Logo
CustomersBlogPricingDemo
SIGN UP NOWBOOK A DEMO

What is the Fiscal Year for AC Immune?

Date: November 14, 2026


AC Immune's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.

Current Fiscal Year Overview

Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026

Quarterly Breakdown

Q1

Jan 1, 2026 – Mar 31, 2026

Q2

Apr 1, 2026 – Jun 30, 2026

Q3

Jul 1, 2026 – Sep 30, 2026

Q4

Oct 1, 2026 – Dec 31, 2026

Company Information

Headquarters

Lausanne, Vaud

Industry

Biotechnology Research

Stock Symbol

ACIU

Website
https://acimmune.com
Description

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.


Use Salesmotion for Account Data and Insights

Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like AC Immune and uncover key business information that drives smarter conversations.

Book a demo today to strengthen your sales strategy with powerful data and actionable insights.

BOOK A DEMO